TABLE 4.
Ovarian stimulation methods in childhood, adolescent, and young adult patients with breast cancer and hematologic malignancy
| (a) Breast cancer | ||||||
|---|---|---|---|---|---|---|
| Institutions, n | COS, n (%) | AI, n (%) | ||||
| Pre | Post | Pre | Post | Pre | Post | |
| Embryos | 87 | 110 | 82/87 (94.0) | 109/110 (99.1) | 51/81 (62.9) | 86/103 (83.5)* |
| Oocytes | 64 | 81 | 61/64 (95.3) | 79/81 (97.5) | 41/60 (68.3) | 73/79 (92.4)* |
| (b) Hematologic malignancy | ||||||
|---|---|---|---|---|---|---|
| Institutions, n | COS, n (%) | Random‐start COS, n (%) | ||||
| Pre | Post | Pre | Post | Pre | Post | |
| Embryos | 53 | 69 | 52/53 (98.1) | 69/69 (100) | 23/49 (46.9) | 54/68 (79.4)* |
| Oocytes | 50 | 60 | 49/50 (98.0) | 59/60 (98.3) | 24/46 (52.1) | 54/59 (91.5)* |
Pre, 2011–2015, i.e., before publication of the Japan Society of Clinical Oncology Clinical Practice Guidelines 2017 for Fertility Preservation in Childhood, Adolescent, and Young Adult Cancer Patients 8 , 9 ; post, 2016–2019, i.e., from shortly before to after publication of the guidelines. *p < 0.05 vs. ratio during 2011–2015 (pre).
Abbreviations: AI, aromatase inhibitor; COS, controlled ovarian stimulation.